RENAL DENERVATION: NEW DATA FROM THE LATEST PIVOTAL TRIALS

Sunday, February 26, 2023

10:30 AM – 12:00 PM ET

Moderator(s)

Eric A. Secemsky, MD, MSc

Director of Vascular Intervention
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Abbott, Bayer, BD, Boston Scientific, Cook, CSI, Inari, Medtronic, Philips, Shockwave and VentureMed.: Advisor (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Consulting fees or other remuneration (Ongoing), Grant/Research Support (Ongoing), Other Research Support (Ongoing), Scientific Advisory Board (Ongoing)
Vasilios Papademetriou, MD, DSc

Director Interventional Hypertension and Vascular Medicine
Georgetown University/VAMC
Washington, District of Columbia, United States

No relationships to disclose
Michael Weber, MD

Professor of Medicine
SUNY Downstate Medical College
Palm Beach Gardens, Florida, United States

Disclosure(s): Ablative Solutions: Consultant/Advisory Board (Ongoing); Medtronic: Consultant/Advisory Board (Ongoing); ReCor: Consultant/Advisory Board (Ongoing)

Disclosure(s):

Eric A. Secemsky, MD, MSc: Abbott, Bayer, BD, Boston Scientific, Cook, CSI, Inari, Medtronic, Philips, Shockwave and VentureMed.: Advisor (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Consulting fees or other remuneration (Ongoing), Grant/Research Support (Ongoing), Other Research Support (Ongoing), Scientific Advisory Board (Ongoing)

Michael Weber, MD: Ablative Solutions: Consultant/Advisory Board (Ongoing); Medtronic: Consultant/Advisory Board (Ongoing); ReCor: Consultant/Advisory Board (Ongoing)